Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177909 | 0.82 | PDE2A (0.43) | KITLRRK2MEN1KMT2ANPC1 | |
| SCHEMBL30823299 | 0.82 | PDE2A (0.43) | KITLRRK2MEN1KMT2ANPC1 | |
| SCHEMBL31143861 | 0.80 | EGFR (0.46) | EGFRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL27201498 | 0.76 | NPC1 (0.47) | LRRK2NPC1RAB9AMAOBCSF1R | |
| SCHEMBL21177860 | 0.76 | P2RY12 (0.48) | KITRAB9ACSF1RNTRK1NTRK2 | |
| SCHEMBL17440928 | 0.76 | MAOB (0.45) | LRRK2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21179152 | 0.76 | CYP1A2 (0.46) | LRRK2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2422028 | 0.75 | LMNA (0.59) | KITEGFRLRRK2MEN1KMT2A | |
| SCHEMBL30615392 | 0.75 | LMNA (0.59) | KITEGFRLRRK2MEN1KMT2A | |
| SCHEMBL21178784 | 0.74 | MAOB (0.45) | LRRK2NPC1RAB9AMAOBCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | KIT 1107/4885EGFR 979/4885LRRK2 1278/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | KIT 1107/4885EGFR 979/4885LRRK2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.